MOTS-c

Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). Discovered in 2015 by Changhan Lee and colleagues at the University of Southern California, MOTS-c was the first mitochondrial-derived peptide (MDP) shown to regulate nuclear gene expression and systemic metabolism — establishing a new paradigm of mitochondrial-to-nuclear retrograde signaling.

The identification of MOTS-c was part of a broader re-evaluation of the mitochondrial genome. For decades, mitochondrial DNA (mtDNA) was thought to encode only 13 proteins (all components of the electron transport chain), 22 tRNAs, and 2 rRNAs. The discovery of biologically active peptides encoded within the ribosomal RNA genes — beginning with humanin in 2001 and followed by the SHLP peptides and MOTS-c — revealed that the mitochondrial genome's coding capacity had been substantially underestimated.

MOTS-c has been described as an "exercise mimetic" because it activates many of the same metabolic pathways that are activated by physical exercise, most notably AMPK (AMP-activated protein kinase) signaling. In preclinical studies, MOTS-c administration has improved insulin sensitivity, prevented diet-induced obesity, enhanced exercise capacity, and reversed age-related metabolic dysfunction. Endogenous MOTS-c levels have been found to decline with age and to increase in response to exercise — correlations that have fueled interest in its potential role in metabolic aging and physical fitness.

Structure and Sequence

Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)

• Molecular weight: Approximately 2,174 Da
• Encoding gene: MT-RNR1 (mitochondrial 12S rRNA gene), within a short ORF (sORF)
• Genome of origin: Mitochondrial DNA (not nuclear DNA)
• Net charge: Positive (multiple Arg, Lys residues)
• Post-translational modifications: None characterized to date
• Species conservation: The MOTS-c sequence shows variation across species, reflecting mitochondrial DNA polymorphisms; human MOTS-c differs from rodent MOTS-c at several positions

Notably, a common mitochondrial DNA polymorphism (m.1382A>C) in the MT-RNR1 gene alters MOTS-c at position 14 (Lys to Gln), creating a variant designated MOTS-c K14Q. This variant has been associated with altered metabolic phenotypes in population studies, providing genetic evidence for MOTS-c's metabolic relevance.

Mechanism of Action

AMPK Activation

MOTS-c's primary metabolic mechanism involves activation of AMPK, the master cellular energy sensor:

• MOTS-c activates AMPK through an increase in the cellular AMP/ATP ratio, mimicking the energetic stress produced by exercise
• The increase in AMP/ATP is mediated by MOTS-c's inhibition of the folate-methionine cycle, specifically at the level of 5-methyl-tetrahydrofolate (5-Me-THF) accumulation
• AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator, accumulates as a consequence of the de novo purine biosynthesis pathway disruption
• AMPK activation triggers a cascade of metabolic effects including enhanced glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy

Nuclear Translocation and Gene Regulation

A landmark finding was the demonstration that MOTS-c translocates to the nucleus in response to metabolic stress:

• Under conditions of glucose restriction or oxidative stress, MOTS-c accumulates in the nucleus
• Nuclear MOTS-c interacts with transcription factors and chromatin-modifying complexes
• This represents a direct mitochondrial-to-nuclear signaling mechanism — a mitochondrial-encoded peptide regulating nuclear gene expression
• MOTS-c regulates the expression of genes involved in the antioxidant response, including those controlled by ARE (antioxidant response element)/Nrf2 signaling

Metabolic Pathway Modulation

Through AMPK and direct nuclear effects, MOTS-c modulates several metabolic pathways:

• Glucose metabolism — Enhanced glucose uptake in skeletal muscle through GLUT4 translocation; improved insulin signaling
• Fatty acid oxidation — Increased beta-oxidation through AMPK-mediated phosphorylation of ACC (acetyl-CoA carboxylase)
• Mitochondrial biogenesis — Upregulation of PGC-1alpha and downstream mitochondrial biogenesis programs
• One-carbon metabolism — Disruption of the folate cycle, with downstream effects on purine synthesis and methylation
• Inflammation — Reduction of pro-inflammatory cytokine production; modulation of macrophage polarization

Exercise-Related Signaling

MOTS-c mimics exercise at the molecular level:

• Activates the same AMPK/PGC-1alpha signaling axis as physical exercise
• Enhances fatty acid oxidation and glucose utilization in skeletal muscle
• Improves mitochondrial function and oxidative capacity
• Endogenous MOTS-c levels increase during acute exercise in humans, suggesting it functions as an exercise-responsive signaling molecule

Research Summary

Pharmacokinetics

Formal pharmacokinetic studies of MOTS-c are limited, with most data derived from preclinical models:

• Endogenous levels: Detectable in human plasma at approximately 0.1-1 ng/mL; levels vary by age, metabolic status, and physical activity
• Half-life: Not formally characterized in published human studies; preclinical data suggests a half-life of hours rather than minutes, relatively long for a small peptide
• Administration route: Intraperitoneal injection in most mouse studies; subcutaneous administration under investigation
• Tissue distribution: Detected in multiple tissues including skeletal muscle, brain, liver, and plasma; not confined to tissues of mitochondrial origin
• Nuclear accumulation: Under metabolic stress conditions, MOTS-c accumulates in the nucleus, suggesting active transport mechanisms
• Age-related dynamics: Circulating levels decline with age in both humans and mice, potentially contributing to age-related metabolic decline
• Exercise-induced changes: Acute exercise increases circulating MOTS-c levels in humans; chronic exercise may affect basal levels

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for research peptides. Always consult a qualified healthcare professional.

Standard Subcutaneous Protocol

Reconstitution (10 mg vial)

• Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration
• At this concentration: 5 mg = 1.0 mL (100 units) on a U-100 insulin syringe
• One 10 mg vial = 2 doses at 5 mg

Cycle Guidelines

• Cycle length: 4–8 weeks on, 4 weeks off
• Route: Subcutaneous injection
• Injection timing: Morning on training days; some protocols suggest pre-exercise (30–60 min before)
• Frequency: 3–5 injections per week (commonly Mon/Wed/Fri or 5 days on, 2 days off)

Common Discussion Topics

1. Exercise mimetic potential — MOTS-c's ability to activate exercise-like metabolic pathways without physical activity is its most discussed property, with particular interest from aging and metabolic disease research communities
2. Aging and longevity — The age-related decline in endogenous MOTS-c and its ability to reverse age-related metabolic dysfunction position it as a candidate geroprotective agent
3. Mitochondrial-nuclear communication — MOTS-c's nuclear translocation represents a novel signaling paradigm that has expanded understanding of mitochondrial biology
4. Metabolic disease — Preclinical efficacy in obesity and insulin resistance models drives discussion of potential applications in metabolic syndrome and type 2 diabetes
5. Genetic variants — The m.1382A>C polymorphism (MOTS-c K14Q) and its metabolic associations represent early pharmacogenomic evidence
6. Comparison with humanin — Often discussed alongside humanin as the two best-characterized mitochondrial-derived peptides, with MOTS-c being metabolic-focused and humanin being neuroprotection-focused

Limitations of Current Research

1. No human clinical trials — All interventional data comes from rodent studies; human data is limited to observational and exercise physiology studies
2. Limited pharmacokinetic data — Formal PK/PD characterization in humans has not been published
3. Species-specific sequence differences — MOTS-c sequence varies across species due to mitochondrial DNA polymorphisms, complicating translational interpretation
4. Mechanism complexity — The folate cycle disruption mechanism may have implications beyond metabolic benefit that require further characterization
5. Regulatory status — Research compound only; not approved for any clinical indication

Related Compounds

• Humanin — another mitochondrial-derived peptide (from the 16S rRNA gene) with neuroprotective and anti-apoptotic properties
• SS-31 (Elamipretide) — a mitochondria-targeted peptide that acts on cardiolipin in the inner mitochondrial membrane
• SHLP1-6 — small humanin-like peptides, additional MDPs encoded within the 16S rRNA gene
• AICAR — a pharmacological AMPK activator that shares pathway activation with MOTS-c
• Metformin — an AMPK-activating drug used for type 2 diabetes, sometimes compared to MOTS-c for its exercise-mimetic properties